Quantcast

Latest Roswell Park Cancer Institute Stories

2009-02-16 10:00:00

Updated guidelines for physicians that represent best practices for using magnetic resonance imaging (MRI) to newly diagnose breast cancer and to make treatment decisions for breast cancer were published today in the Journal of the National Comprehensive Cancer Network. Breast radiologists and surgeons at the Seattle Cancer Care Alliance (SCCA) and the Roswell Park Cancer Institute in Buffalo, N.Y. authored the paper upon which the guidelines are based. The SCCA breast imaging program led by...

2009-02-10 07:59:00

NCCN names Cold Spring Publishing, LLC, as the new publishing company for JNCCN - The Journal of the National Comprehensive Cancer Network. Cold Spring Publishing is a newly formed medical publishing company led by Jack Gentile, founder of PRR, Inc., and Conor Lynch. Content in JNCCN covers the entire spectrum of cancer care and features updates on the NCCN Clinical Practice Guidelines in Oncology(TM). FORT WASHINGTON, Pa., Feb. 10 /PRNewswire-USNewswire/ -- JNCCN - The Journal of the...

2009-02-03 08:03:00

NCCN announces new updates to the NCCN Guidelines for Breast Cancer and Breast Cancer Risk Reduction Guidelines. Noteworthy additions include new recommendations on when to use MRIs in breast cancer evaluations, statements discouraging the use of PET/CT scanning for evaluative purposes, and new cosmetic recommendations for women undergoing reconstructive surgery. FORT WASHINGTON, Pa., Feb. 3 /PRNewswire-USNewswire/ -- The National Comprehensive Cancer Network (NCCN) announces important...

2009-01-15 09:15:00

NCCN recently received a $4 million research grant from Wyeth Pharmaceuticals to evaluate the safety and effectiveness of temsirolimus in the treatment of solid tumors. Temsirolimus is currently approved to treat advanced renal cell carcinoma (RCC). This grant is the largest research award received by NCCN to date. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, Pa., Jan. 15 /PRNewswire-USNewswire/ -- The National Comprehensive...

2009-01-14 07:00:00

NCCN, in collaboration with the Abu Dhabi Health Services Company (SEHA), announce The Second Annual Middle East and North Africa NCCN Guidelines Congress scheduled for April 23 - 26, 2009 in Abu Dhabi, United Arab Emirates (UAE). The program will present the latest developments in treating common cancers and generate discussions around developing regional guidelines. FORT WASHINGTON, Pa., Jan. 14 /PRNewswire-USNewswire/ -- The National Comprehensive Cancer Network (NCCN) is pleased to...

2008-11-03 09:00:40

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York City, November 10-12, 2008. The conference will be held at The New York Palace Hotel. Management will be available to meet with investors or licensing partners November 10-11. Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, will give a presentation on the Company's lead compounds and development...

2008-10-30 15:00:38

A U.S. company says it's started initial human safety testing of a drug designed to treat exposure to radiation from nuclear weapons or a nuclear accident. Cleveland BioLabs Inc. said it dosed its first healthy volunteer this month in the human safety study required by the U.S. Food and Drug Administration for the drug Protectan CBLB502. The safety trial involves single injections of Protectan CBLB502 in ascending dose groups of six healthy volunteers each. Participants in the study will...

2008-10-27 09:00:41

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced results of a series of studies demonstrating Protectan CBLB612's ability to substantially reduce myelosuppression (the most common rate limiting adverse effect of chemotherapy) caused by a widely used chemotherapeutic drug, cyclophosphamide (Cytoxan, Neosar, CTX). Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, stated: "Our previous studies established Protectan CBLB612's activity as a potent...

2008-10-21 09:00:54

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will present at the 2008 BIO Investor Forum in San Francisco, October 29-31, 2008. The conference will be held at The Palace Hotel in San Francisco. Management will be available to meet with investors or licensing partners October 29-30. Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, will give a presentation on the Company's lead compounds and development strategy on October 30, at...

2008-10-15 09:00:47

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on October 14, the first healthy volunteer was dosed in the initial human safety study for Protectan CBLB502, a drug under development for the treatment for Acute Radiation Syndrome (ARS). Protectan CBLB502 is being developed under the FDA's animal efficacy rule to treat radiation injury following exposure to radiation from nuclear or radiological weapons, or from nuclear accident. This approval pathway requires demonstration of...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related